Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

567P - Phase Ib study of Intraperitoneal (IP) administration of nivolumab plus ipilimumab in patients with recurrent gynaecologic malignancies with peritoneal involvement

Date

10 Sep 2022

Session

Poster session 09

Topics

Immunotherapy

Tumour Site

Gynaecological Malignancies

Presenters

Emily Hinchcliff

Citation

Annals of Oncology (2022) 33 (suppl_7): S235-S282. 10.1016/annonc/annonc1054

Authors

E. Hinchcliff1, A. Mosely2, S. Hull2, S. Westin3, A. Sood3, K. Schmeler3, J. Taylor2, S. Huang4, R. Sheth4, K. Lu2, A. Jazaeri3

Author affiliations

  • 1 Gynecologic Oncology, Northwestern University, 60611 - Chicago/US
  • 2 Gynecologic Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Gynecologic Oncology And Reproductive Medicine Department, The MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Interventional Radiology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 567P

Background

The peritoneal cavity is a frequent site of metastasis and recurrence for gynecologic malignancy, which has led to intraperitoneal (IP) administration for traditional cytotoxic chemotherapy. IP immunotherapy is a recognized but under explored area of investigation. The objective of this trial was to determine the recommended phase II dosing (RP2D) of IP-administered nivolumab and ipilimumab in patients with peritoneal carcinomatosis due to gynecologic malignancy.

Methods

In this open-label Phase Ib study (NCT03508570), initial cohorts received IP nivolumab monotherapy (starting dose 1mg/kg escalated to 3mg/kg), followed by cohorts treated with combination nivolumab and ipilimumab (administered IP every 2 and 6 weeks, respectively) guided by a Bayesian design. Maximum combination dose was capped at nivolumab 3mg/kg plus ipilimumab 1mg/kg. Toxicity and response were evaluated using CTCAE v5.0 and modified RECIST v1.1.

Results

23 patients were enrolled; 18 ovarian, 2 endometrial, and 3 with cervical malignancy. The median number of prior lines of therapy was 2 (1-8); one had received prior IP chemotherapy. Median number of cycles was 2 (range 1-7). No DLTs or drug-related SAEs were noted. Grade ≥3 immune related adverse events occurred in 2 (8.7%) patients. One patient developed pancreatitis requiring study discontinuation successfully managed with steroids and the other had asymptomatic pancreatic enzyme elevation. Issues infusing via IP port occurred in 3 patients; all were managed without impacting therapy. There were 16 efficacy-evaluable patients. Partial response was observed in 18.8% (3/16), including 1 patient each with ovarian, endometrial, and cervical cancers. The 7 non-evaluable patients all stopped therapy within the first cycle for progression or death but none had trAE. The median duration of response was 8 months (6-14, two ongoing). An additional 3 patients had stable disease.

Conclusions

The IP administration of nivolumab and ipilimumab is safe, feasible and demonstrated promising preliminary evidence of clinical benefit in advanced gynecologic malignancy. The RP2D based on this study is IP nivolumab 3mg/kg q2wks plus ipilimumab 1mg/kg q6wks.

Clinical trial identification

NCT03508570.

Editorial acknowledgement

Legal entity responsible for the study

The University of Texas MD Anderson Cancer Center.

Funding

Bristol Meyers Squibb.

Disclosure

S. Westin: Financial Interests, Personal and Institutional, Sponsor/Funding, consulting: AstraZeneca, Clovis, GSK, Mereo, Genentech; Financial Interests, Institutional, Sponsor/Funding: Bayer, Cotinga Pharmaceuticals, Novartis; Financial Interests, Personal and Institutional, Sponsor/Funding: OncXerna; Financial Interests, Personal and Institutional, Invited Speaker, consulting: Zentalis; Financial Interests, Personal, Other, consulting: ImmunoGen, eqrx, Lilly, Caris, Vincerx, Mersana, Karyopharm, Merck. A. Sood: Financial Interests, Personal, Other, consulting: Merck, GSK, Kiyatec; Financial Interests, Personal, Stocks/Shares: Biopath. A. Jazaeri: Financial Interests, Institutional, Sponsor/Funding: Iovance, Lilly, Ziopharm, AstraZeneca, Merck, Immatics; Financial Interests, Personal and Institutional, Sponsor/Funding, consulting: BMS, Aravive; Financial Interests, Personal, Other, consulting: Alkermes, Macrogenetics, Obsedian, Nuprobe, Agenus, Instill Bio, Immune-Onc, GSK, Avengebio, EMD-Serono, Gherson Lehrman Group. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.